A recent study found that application of the CCR2 antagonist inhibited the tumorigenicity via reducing the infiltration of TAMs and increasing the infiltration of cytotoxic CD8 positive lymphocytes in a murine hepatocellular carcinoma model (11). This evidence concerns the gene CD8A and hepatocellular carcinoma.